N-[2-[[2-[(2-氨基乙基)氨基]乙基]氨基]乙基]-乙酰胺 | 141998-21-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[2-[[2-[(2-氨基乙基)氨基]乙基]氨基]乙基]-乙酰胺
• 中文别名: N1-乙酰三亚乙基四胺
• 英文名称: N-acetyl-3,6-diazaoctane-1,8-diamine
• 英文别名: N1-monoacetyltriethylenetetramine；N1-acetyltriethylenetetramine；MAT；N-[2-[2-(2-aminoethylamino)ethylamino]ethyl]acetamide
• CAS: 141998-21-2
• 化学式: C₈H₂₀N₄O
• 分子量: 188.273
• InChiKey: GMXQUOKWLVCFEG-UHFFFAOYSA-N

物化性质

• 熔点：
  >229°C (dec.)
• 沸点：
  401.5±30.0 °C(Predicted)
• 密度：
  1.002±0.06 g/cm3(Predicted)
• 溶解度：
  可微溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  79.2
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-[[2-[(2-氨基乙基)氨基]乙基]氨基]乙基]-乙酰胺 、 3,4,9,10-苝四羧酸二酐 以 1,4-二氧六环 、 N,N-二甲基乙酰胺 为溶剂， 反应 6.0h， 生成 N,N'-bis(8-acetamido-3,6-diazaoctyl)-3,4,9,10-perylenetetracarboxylic diimide
  参考文献：
  名称：

  The number and distances of positive charges of polyamine side chains in a series of perylene diimides significantly influence their ability to induce G-quadruplex structures and inhibit human telomerase

  摘要：

  We have synthesized eight polyamine perylene diimides to conjugate the efficiency of perylene derivatives in stabilizing G-quadruplex structures and the polyamines' biological activity, due to specific interactions with different DNA domains. Our study was carried out by investigating the ability of these derivatives to induce inter- and intramolecular G-quadruplex structures by polyacrylamide gel electrophoresis (PAGE) and to inhibit telomerase in a modified TRAP assay. The two properties appear to be satisfactorily correlated and they show that the number and distances of positive charges in the side chains dramatically influence both these features. Although our previous studies on perylene derivatives with mono-positively charged side chains indicated that self assembly in aqueous solution leads to a major efficiency, the result observed with the spermine derivative suggests that a too strong aggregation is unfavourable, because it determines a lower solubility of the compounds. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.065
• 作为产物：
  描述：

  三乙烯四胺 、 α-D(+)-五乙酰葡萄糖 以 乙醇 为溶剂， 反应 20.0h， 以39%的产率得到N-[2-[[2-[(2-氨基乙基)氨基]乙基]氨基]乙基]-乙酰胺
  参考文献：
  名称：

  单或双乙酰化聚乙烯聚亚胺衍生物的区域专一性合成

  摘要：

  摘要 以α-D-五乙酰基葡萄糖为乙酰化剂合成了乙酰化聚乙烯多胺CH3CONHCH2(CH2-NH-CH2)CH2NH2 (n=1,2;)。

  DOI：

  10.1080/00397919208019313

文献信息

• TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
  申请人：Cooper Garth James Smith

  公开号：US20130108709A1

  公开（公告）日：2013-05-02

  Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

  药物组合物和治疗方法，用于治疗患有或有风险患有各种疾病、疾病和疾病的受试者，包括线粒体相关疾病、疾病和疾病，包括呼吸链障碍，以及与线粒体肿胀、线粒体功能障碍、线粒体泄漏、氧化应激、线粒体数量增加、线粒体和线粒体相关蛋白质质量增加以及线粒体和相关蛋白质表达增加至少部分有关的疾病、疾病和疾病。
• Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits
  申请人：COOPER Garth James, Smith

  公开号：US20150196500A1

  公开（公告）日：2015-07-16

  Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

  药物组合物和方法，用于治疗患有或有患各种疾病，疾病和疾病的风险，包括与线粒体相关的疾病，疾病和疾病，包括呼吸链疾病，以及与线粒体肿胀，线粒体功能障碍，线粒体泄漏，氧化应激，线粒体数量增加，线粒体和线粒体相关蛋白质质量增加，以及线粒体和相关蛋白质表达增加至少部分相关的疾病，疾病和疾病。
• Dosage forms and related therapies
  申请人：PhilERA New Zealand Limited

  公开号：US10543178B2

  公开（公告）日：2020-01-28

  This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

  本发明部分涉及新型剂量、剂型和给药途径，所述剂量和剂型含有一种或多种铜螯合剂，例如一种或多种三苯汀活性剂，包括三苯汀类似物、三苯汀盐、三苯汀原药和三苯汀衍生物，可用于治疗疾病、失调和病症，包括铜可能起作用的适应症。
• Use of trientine to deliver copper to ischemic tissue
  申请人：INNOLIFE CO., LTD.

  公开号：US11033579B2

  公开（公告）日：2021-06-15

  Methods of ischemic tissue repair and regeneration through promoting tissue redistribution and reuse of copper by administering a composition comprising a copper chelating tetramine, such as trientine. Methods and compositions for increasing intracellular copper lever and/or inducing repair of an ischemic tissue in an individual. Increased copper level in an ischemic tissue may promote copper-dependent HIF-1 transcriptional activities and tissue repair.

  通过施用包含铜螯合四胺（如三尖杉碱）的组合物，促进组织铜的再分布和再利用，从而实现缺血组织修复和再生的方法。增加细胞内铜杠杆和/或诱导缺血组织修复的方法和组合物。缺血组织中铜含量的增加可促进铜依赖性 HIF-1 转录活动和组织修复。
• Copper antagonist compounds
  申请人：Cooper J.S. Garth

  公开号：US20050159364A1

  公开（公告）日：2005-07-21

  Copper antagonist compounds and the use of such compounds in methods for the treatment, prevention, or amelioration of various disorders that would be benefited by reduction in copper, for example copper (II), including neurodegenerative and other disorders.

  铜拮抗剂化合物，以及将此类化合物用于治疗、预防或改善各种可通过减少铜（例如铜(II)）含量而获益的疾病（包括神经退行性疾病和其他疾病）的方法。